The official gazette of October 6, 2026, announced a significant price reduction for Eliquis, a medication known as apixaban, produced by the pharmaceutical company Bristol-Myers Squibb. This drug is used to prevent blood clots and is commonly prescribed for patients with conditions like atrial fibrillation or those who have had a recent heart attack or stroke. Starting November 1, 2026, the cost of all dosages of Eliquis will decrease by more than 50%. The price cuts apply to several forms of the drug, including dosages of 0.15 mg, 0.5 mg, 1.5 mg, 2 mg, 2.5 mg, and 5 mg, with specific reductions ranging from 51.9% to 52.2%. This change comes at a time when generic versions of apixaban have recently been approved for reimbursement, potentially increasing access to the medication. The price revision for Eliquis reflects a broader trend in the pharmaceutical industry, where manufacturers sometimes adjust prices in response to market conditions or the availability of cheaper alternatives. In this case, the move could benefit patients and healthcare systems by reducing the financial burden of treatment for conditions that require long-term use of anticoagulants. In contrast, another medication, Diffu-K 600 mg (potassium chloride) produced by Teopharma, is facing a price increase. This drug is used to treat potassium deficiencies, a condition that can occur due to various health issues or treatments. The most common form of the medication, a box containing 40 capsules (CIP: 34009 329 059 9 7), will see its price rise by 1.5%, increasing from 1.98 euros to 2.01 euros. This increase will take effect on November 15, 2026. The differing price adjustments for these two medications highlight the complex and often unpredictable nature of pharmaceutical pricing. While Eliquis is becoming more affordable, Diffu-K is becoming slightly more expensive, which could affect patients who rely on these treatments. These changes may also influence prescribing practices and patient choices in the healthcare system.